After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation?

In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival.

Randomised multicentre non-inferiority trial · The Lancet 2025

Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/

This is a summary of trial findings, not an individual treatment recommendation.

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en